VitaDX
- Company typePrivate
- Founded2015
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
VitaDX firmographics
Firmographics- Name
- VitaDX
- Legal name
- VitaDx International (VitaDx)
- Website
- https://vitadx.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
VitaDX industry classification
Industry- Product category
- AI Cancer Diagnostics Software
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM), Medical Imaging AI (HDAAAEAH)
Keywords
Where VitaDX is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
VitaDX business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Testing Services: VitaDX generates revenue through the sale of VisioCyt® Bladder diagnostic tests to healthcare facilities and laboratory networks. The test is covered under the French RIHN 2.0 program at 100% for patients enrolled in the TVNIM registry, with a patient contribution of 253 euros for routine prescriptions.
- Technology Licensing: The company licenses its VisioCyt® technology platform for different cancer applications, including the ongoing development partnership with MEDIPATH for thyroid cancer diagnosis under the France 2030 program.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | RIHN 2.0 Coverage - Registry patients |
| Transaction based/ take rate | Pay-as-you-go | Routine Clinical Practice |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
VitaDX product offering
Product offeringCore offering
VitaDX develops and commercializes AI-powered diagnostic solutions applied to cytology through its proprietary VisioCyt® deep learning platform. The company sells VisioCyt® Bladder, a CE IVDR Class C in vitro diagnostic medical device that analyzes digitized urine cytology slides to detect and monitor urothelial carcinoma. The technology is also being extended to thyroid cancer diagnosis and asymptomatic bladder cancer screening applications.
Product overview
VitaDX develops and commercializes cancer diagnostic solutions combining image analysis and artificial intelligence applied to cytology through its proprietary VisioCyt® technology platform. The core product VisioCyt® Bladder (CE IVDR Class C) is a commercialized solution for bladder cancer diagnosis and monitoring from urine samples. Two additional products are in development: VisioCyt® Screening for bladder cancer screening in high-risk asymptomatic patients, and VisioCyt® Thyroid for thyroid cancer diagnosis from fine-needle aspiration. All products use deep learning and computer vision algorithms to analyze digitized cytology slides, with VisioCyt® Bladder showing mean sensitivity of 80.9% and 93.7% sensitivity for high-grade cancers.
Differentiator
Problem solved
Functional benefit
Brands
- VisioCyt®: AI-powered technology platform using deep learning and computer vision algorithms to analyze and diagnose digitized cytology slides for cancer detection
- VisioCyt® Bladder
- VisioCyt® Screening
- VisioCyt® Thyroid
Products and services
- VisioCyt® Bladder CE IVDR Class C in vitro diagnostic medical device that performs automated cytology analysis on digitized urine samples using deep learning algorithms to detect and classify urothelial carcinoma cells for diagnosis and surveillance of bladder cancer. Mean sensitivity of 80.9% with 93.7% sensitivity for high-grade cancers.
- VisioCyt® Screening AI-powered bladder cancer screening test in development for asymptomatic, high-risk patients, addressing the current absence of a screening test for bladder cancer.
- VisioCyt® Thyroid AI-based diagnostic test in development for thyroid cancer detection from fine-needle aspiration samples, developed in collaboration with MEDIPATH under the France 2030 program.
Quantifiable outcome
- Mean sensitivity: 80.9%; Sensitivity for high-grade cancer: 93.7%; Sensitivity for low-grade cancer: 66.7%; Specificity: 61.8%
- +1 more outcomes
Companies that use VitaDX
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
VitaDX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
VitaDX partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Association Française d'Urologie (AFU)coreAFU is deploying a national registry for TVNIM (non-muscle-invasive bladder tumors) to collect real-world patient data. VitaDX's VisioCyt® Bladder is integrated as one of four diagnostic tests being evaluated in the registry protocol. The partnership enables structured clinical data collection supporting reimbursement applications and provides access to urology practices across France for test distribution.
- BiogroupcoreStrategic partnership with Biogroup, one of France's largest networks of medical biology laboratories with over 900 locations, to expand urine sample collection points for VisioCyt® Bladder testing. Patients can have their samples collected at Biogroup laboratories and prescribed by participating urologists in the TVNIM registry.
- Pfizer Healthcare Hub FranceminorSelected among 5 startups for the Pfizer Healthcare Hub France program, providing 9 months of customized dual mentorship with a Pfizer pharmaceutical industry expert and a WILCO entrepreneurship mentor to accelerate development and market access.
- WILCOminorWILCO provides startup acceleration services and entrepreneurship mentorship as part of the Pfizer Healthcare Hub France program, supporting VitaDX's business development and go-to-market strategy.
- MEDIPATH FrancecoreCollaboration with MEDIPATH, independent group of pathologists specializing in cancer diagnosis and proximity expertise, for deployment of VisioCyt® for early bladder cancer diagnosis. Additionally, joint development of VisioCyt® Thyroid under the France 2030 medical imaging program, where MEDIPATH provides pathology expertise and clinical validation infrastructure.
Scale indicators4 records
Recent moves6 records
Expansion highlights7 records
VitaDX competitors and assessment
Company assessmentDirect peers
- Paige.AI: AI-based digital pathology platform for cancer diagnosis using deep learning on whole-slide images. Directly comparable as a SaMD for AI-driven cancer detection from digitized pathology slides, with overlapping technology and customer base (pathology labs, hospitals).
- Ibex Medical Analytics: AI-powered cancer diagnostics platform for pathology, including prostate and breast cancer detection from biopsy slides. Closely comparable as an AI pathology company targeting hospital and laboratory workflows with regulatory-cleared diagnostic software.
- PathAI: AI-powered pathology platform for both diagnostic and drug development applications. Comparable as a deep-learning pathology company with similar technology stack and customer overlap with anatomopathology laboratories.
- Pacific Edge Diagnostics: Developer of Cxbladder, a non-invasive urine-based diagnostic test for bladder cancer detection and monitoring. Direct clinical-area peer, addressing the same bladder cancer surveillance use case that VitaDX's VisioCyt® Bladder targets.
Broad incumbents
- Owkin: French-founded AI diagnostics and drug discovery company with broader oncology portfolio spanning pathology, multimodal AI, and biopharma partnerships. Comparable technology stack and French/EU footprint, but with broader scope beyond cytology.
- Lunit: Korean AI medical imaging company with FDA-cleared products for cancer detection (notably Lunit INSIGHT for mammography and Lunit SCOPE for pathology). Comparable as a publicly listed AI diagnostics player with similar deep-learning + imaging approach but broader modality coverage.
- Tempus Labs: US-based technology company combining AI with multi-modal data (imaging, molecular, clinical) for precision oncology. Comparable as an AI-driven cancer diagnostics platform, but at significantly larger scale with broader indications including pathology.
Emerging players
- Mindpeak: Hamburg-based AI pathology startup offering deep-learning-based analysis tools for pathology labs including IHC quantification and cell detection. Comparable as an EU AI pathology player targeting laboratory workflows, with overlapping customer profile but smaller scale.
- Nucleai: Israel-based AI spatial biology and pathology company providing tumor microenvironment analysis from H&E and multiplexed images. Comparable as an AI pathology company with similar deep-learning approach, but focused on spatial biology research applications rather than routine IVD diagnostics.
- Nonagen Bioscience: Developer of Oncuria, a non-invasive multiplex urine biomarker test for bladder cancer detection and monitoring. Direct clinical-area peer in bladder cancer diagnostics with a complementary (protein biomarker) but overlapping product approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VitaDX social profiles
Digital presenceVitaDX compliance and trust
Trust signalCompliance1 record
VitaDX financial estimates
Financial estimateRevenue estimate
Valuation estimate
VitaDX leadership team
Management profileNumber of profiles
Profiles9 records
VitaDX funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VitaDX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VitaDX
What does VitaDX do?
VitaDX develops and commercializes AI-powered diagnostic solutions applied to cytology through its proprietary VisioCyt® deep learning platform. The company sells VisioCyt® Bladder, a CE IVDR Class C in vitro diagnostic medical device that analyzes digitized urine cytology slides to detect and monitor urothelial carcinoma. The technology is also being extended to thyroid cancer diagnosis and asymptomatic bladder cancer screening applications.
Is VitaDX a public or private company?
VitaDX is a private company. It is classified as venture growth investor backed and is currently operating.
When was VitaDX founded?
VitaDX was founded in 2015. It employs 11 to 50 people.
Where is VitaDX based?
VitaDX is headquartered in Paris, France, in the Europe region.
How does VitaDX make money?
Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are technology Licensing.
Who are VitaDX's main competitors?
Direct peers on record are Paige.AI, Ibex Medical Analytics, PathAI and Pacific Edge Diagnostics. Broad incumbents are Owkin, Lunit and Tempus Labs. Emerging players are Mindpeak, Nucleai and Nonagen Bioscience.
Does VitaDX have an API?
No public API is recorded for VitaDX.
What industry is VitaDX in?
VitaDX's product category is AI Cancer Diagnostics Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 325413 and its SIC code is 2835.